Alrestatin sodium
Based on 1 publication(s) in Google Scholar
Alrestatin (AY-22284) sodium is an aldose reductase inhibitor. Alrestatin sodium reduces fructose levels in the uterine fluid of mice. Alrestatin sodium interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin sodium decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin sodium enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin sodium can be used in studies related to diabetes and reproductive diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 51876-97-2
- Formule: C14H8NNaO4
- Masse moléculaire:277.21
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Alrestatin sodium
More
Activité biologique
Alrestatin (1-5 mg/mL; 15 min) sodium dose-dependently inhibits basal and tyramine-stimulated 3H-norepinephrine release from rat splenic and pancreatic tissue samples in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Alrestatin (0.15 μg/μL; intrauterine infusion) sodium significantly reduces fructose levels in mouse uterine fluid without altering glucose or sorbitol levels[2].
Alrestatin (1.5 mmol/L; intrauterine injection) sodium significantly reduces sperm capacitation rate and fertilization rate in mice, while co-administration of fructose or sorbitol reverses these effects[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 200-250 g, fasted, anaesthetized)[1]
-
Dosage:0.75 mmol/kg
-
Administration:i.v.; single bolus
-
Result:Produced significantly greater mean incremental plasma insulin levels compared to vehicle.
Reduced mean incremental plasma glucose levels significantly compared to vehicle.
Did not significantly alter basal fasting plasma glucose or insulin levels relative to vehicle when administered without glucose.
Chemical Information
-
CAS No. 51876-97-2
-
Masse moléculaire 277.21
-
Formule C14H8NNaO4
-
SMILES
O=C([O-])CN(C(C1=CC=CC2=CC=CC3=C12)=O)C3=O.[Na+]
-
Synonyms
AY-22284A
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Theriogenology
Expression of aldose reductase in mouse endometrial epithelial cells and its role in sperm capacitation. [Abstract]2023 Oct 1:209:243-250. PMID: 37480702
Pureté et documentation
Références
[1]. Kobric M, et al. Effect of alrestatin sodium on glucose-stimulated insulin secretion in the fasted anaesthetized rat. Horm Metab Res. 1978;10(6):495-500. [Content Brief]
[2]. Lei Y, et al. Expression of aldose reductase in mouse endometrial epithelial cells and its role in sperm capacitation. Theriogenology. 2023;209:243-250. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Alrestatin sodium Related Classifications
HY-B1202A Related Classifications
Powered by Bioz